Navigation Links
Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts

Johns Hopkins scientists have developed a gene-based test to distinguish harmless from precancerous pancreatic cysts. The test may eventually help some patients avoid needless surgery to remove the harmless variety. A report on the development is published in the July 20 issue of Science Translational Medicine.

The investigators estimate that fluid-filled cysts are identified in more than a million patients each year, most of whom have undergone CT or MRI scans to evaluate non-specific symptoms, such as abdominal pain and swelling.

Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator, and his colleagues analyzed precancerous cysts from 19 patients and searched for mutations in 169 cancer-causing genes. They found mutations in the KRAS gene, well-known for its prevalence in pancreatic cancers, and the GNAS gene, which had not previously been associated with pancreatic cancer. In both KRAS and GNAS, the mutations occur at a single coding spot in the DNA, the equivalent of a typo in a word within an entire encyclopedia. KRAS and GNAS genes produce signaling proteins, relaying signals from the cell surface to areas within the cell.

The researchers then tested a total of 132 precancerous pancreatic cysts for mutations in KRAS and GNAS. GNAS mutations were found in more than half of the samples (87 of them), and KRAS mutations occurred in 107 samples. Nearly all (127) had mutations in GNAS, KRAS or both. The mutations occurred in large and small, high- and low-grade cysts, and in all major types of the most common precancerous pancreatic cysts. There were no major differences in age, gender or smoking history for people with GNAS or KRAS mutations in their cysts' cells.

Finally, the investigators tested tissue from pancreatic cancers that had developed in eight people with GNAS-mutated cysts. Seven of the eight had GNAS mutations in their cancer, as well as cells in the cysts.

GNAS and KRAS mutations were not found in benign cysts, although KRAS mutations did appear occasionally in a rare type of cyst with a relatively low potential to become cancerous. These rare, mostly benign cysts are less challenging to diagnose because of their location within the pancreas and type of patient, according to the investigators.

"There has long been a need for accurate, quantitative ways to identify cysts that are more worrisome and to help patients avoid unnecessary surgeries for harmless cysts," says Vogelstein, the Clayton Professor of Oncology at the Johns Hopkins Kimmel Cancer Center.

"Most cysts are benign," says pathologist Ralph Hruban, M.D., director of Hopkins' Sol Goldman Pancreatic Cancer Research Center, "but distinguishing between the harmless and dangerous ones is challenging for doctors and patients alike."

Generally, patients with a cyst that appears harmless and is less than 3 cm in size are monitored to watch for growth of the cyst or other concerning features such as a solid nodule. With cysts that appear more worrisome, surgical removal is often recommended, but the procedure requires removal of a portion of the pancreas as well, and complications like a pancreatic fistula (fluid from the pancreas leaks through the surgical incision), eating difficulties and prolonged recovery can develop, according to Christopher Wolfgang, M.D., Ph.D., associate professor of surgery, pathology and oncology and director of pancreatic surgery at Johns Hopkins.

CT scans, MRI imaging, and enzyme and secreted antigen levels in cyst fluid are imprecise markers for precancerous potential, adds Wolfgang.

Genetic analysis of the kind reported in the new study offers a new way to sort the potential of these cysts to cause malignant trouble.

The investigators caution that cyst fluid removal, an invasive procedure, also has its caveats and can cause bleeding, infection and inflammation in a very small percentage of patients.

Further studies on a larger number of patients must be done before the gene-based test can be widely offered. However, Vogelstein says that the technology for developing a gene-based test in this case is relatively straightforward because "the mutation occurs at one spot in both of the genes."


Contact: Vanessa Wasta
Johns Hopkins Medical Institutions

Related medicine news :

1. Brain Surgery for Mary Tyler Moore to Remove Benign Tumor
2. Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia
3. Hormone test predicts ovarian function after chemotherapy for breast cancer
4. Earlier PSA Test Best Predicts Risk of Dying From Prostate Cancer: Study
5. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
6. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
7. Climate change analysis predicts increased fatalities from heat waves
8. HIV rate in SF could be cut sharply with expanded treatment, study predicts
9. New lung cancer staging system (TNM 7) better predicts local/regional recurrence, study shows
10. Interest in toys predicts effectiveness of autism treatment in toddlers
11. New online tool predicts probability of death from stroke
Post Your Comments:
Related Image:
Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology: